| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
ANI Pharmaceuticals, Inc.$79.49
-1.03 (-1.28%)
C 40Pipeline Score Fair Value Biotech · Commercial
Market Cap
1.70 B
EPS
4.09
P/E Ratio
18.94 $
Value Trade
19.33 M
SEC Financials
Q1 2026Dilution Risk
Revenue
237.46 M
R&D Expenses
10.60 M
Operating CF
58.38 M
Total Assets
1.42 B
Total Liabilities
859.67 M
Equity
562.30 M
D/E Ratio
12,345
4.34 %
Week
2.95 %
1 Month
6.21 %
3 Month
5.21 %
6 Month
134.93 %
5 Year
-72.32 %
All Time
Cash Data
Cash Position
311.18 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 8, 2026
Overview
Volume
351.46 K
52 Week Range
59.61 - 99.50
% held by Insiders
12.36 %
% held by Institutions
104.26 %
Enterprise Value
1.99 B
Total Shares
22.76 M
Short %
17.15 %
Float Shares
19.39 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
C40
Pipeline Score $369M
Pipeline ValueFair Value
Valuation Signal3
Drugs Scored0.7x
rNPV / MCap Top 58%
Micro Cap (rank 381 of 905)
Percentile RankANI Pharmaceuticals, Inc. carries a moderate pipeline score (40/100), with $923M risk-adjusted pipeline value, led by Faricimab in Radiation Retinopathy (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Faricimab Small molecule | Radiation Retinopathy | Phase 3 | NCT05844982 | 49% | $463M | RECRUITING | 600 | - | - | Dec 26, 2029 | - | LOW May 24, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ILUVIEN | diabetic macular edema | Phase 3 | 2025-07-23 | |||
ILUVIEN | diabetic macular edema | Phase 3 | 2025-07-23 | |||
ILUVIEN | diabetic macular edema | Phase 3 | 2025-07-23 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ANIP
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ANI Pharmaceuticals, Inc. (ANIP) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
ANIP
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ANIP
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ANIP
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ANIP Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
ANIP Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ANIPANI Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
ANI Pharmaceuticals, Inc. announced that CEO Nikhil Lalwani will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference. The event will be accessible via a live and archived webcast on the company's website. ANI Pharmaceuticals focuses on developing and commercializing innovative therapeutics across various medical fields.
Read more →ANIPANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance
ANI Pharmaceuticals reported strong financial results for Q1 2026, with net revenues of $237.5 million, a 20.5% increase from the previous year. The company raised its full-year guidance, expecting total revenues between $1.08 billion and $1.14 billion, driven largely by growth in its Rare Disease segment. Cortrophin Gel showed significant revenue growth, and the company is focused on expanding its market presence.
Read more →ANIPANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ET
ANI Pharmaceuticals will release its first quarter 2026 financial results on May 8, 2026. The announcement includes a conference call and webcast hosted by key executives to discuss the results. The company emphasizes its commitment to developing innovative therapeutics and sustainable growth in its Rare Disease business.
Read more →ANIPANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity
ANI Pharmaceuticals has announced the FDA approval and launch of Pimozide Tablets, a generic version of Orap. The launch comes with 180-Day CGT exclusivity, allowing ANI to limit competition in the market. The annual sales for Pimozide Tablets are estimated at around $3.1 million, indicating a promising revenue opportunity for the company.
Read more →ANIPANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release Capsules
ANI Pharmaceuticals has launched Carbamazepine Extended-Release Capsules in 100 mg, 200 mg, and 300 mg dosages, marking a significant addition to its generics portfolio. This launch aims to enhance patient access to essential medications and is expected to tap into a market with annual sales of around $65 million. The company's commitment to quality and compliance remains a priority.
Read more →ANIPANI Pharmaceuticals Announces FDA Approval and Launch of Isosorbide Mononitrate Tablet
ANI Pharmaceuticals has received FDA approval for its Isosorbide Mononitrate Tablet USP, available in 10 mg and 20 mg dosages. This launch emphasizes the company's commitment to providing high-quality, limited-competition products. ANI's CEO highlighted the importance of this approval in reinforcing their R&D capabilities and operational execution.
Read more →ANIPANI Pharmaceuticals Announces Publication of NEW DAY Clinical Trial Results in Ophthalmology
ANI Pharmaceuticals announced the publication of the NEW DAY clinical trial results for ILUVIEN, a treatment for diabetic macular edema, in the journal Ophthalmology. The trial demonstrated ILUVIEN's efficacy, and the publication underscores ANI's commitment to advancing care for patients with this condition. However, safety information highlights potential risks associated with the treatment.
Read more →ANIPANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Financial Guidance
ANI Pharmaceuticals reported record financial results for Q4 and full year 2025, with net revenues of $247.1 million and $883.4 million, respectively. The Rare Disease segment saw substantial growth, particularly with Cortrophin Gel, which is expected to drive future revenue. The company reaffirmed its financial guidance for 2026, anticipating over $1 billion in revenue, with a focus on expanding its Rare Disease business.
Read more →ANIPANI Pharmaceuticals to Present at Upcoming Investor Conferences
ANI Pharmaceuticals announced that CEO Nikhil Lalwani and the executive team will present at upcoming investor conferences. The live and archived webcasts will be available on the company's website, ensuring accessibility for stakeholders. This initiative reflects the company's commitment to engaging with investors and promoting its diverse biopharmaceutical portfolio.
Read more →ANIPANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026, at 8:00 a.m. ET
ANI Pharmaceuticals will announce its fourth quarter and full year 2025 financial results on February 27, 2026. The announcement will be followed by a conference call featuring key executives. The event will be accessible via the company's website, with a replay available for a year. ANI focuses on innovative therapeutics in various medical fields.
Read more →ANIPANI Pharmaceuticals Announces Formation of “FutureVision Advisory Council” to Help Strategically Guide Ophthalmology and Retina Franchise
ANI Pharmaceuticals has formed the FutureVision Advisory Council to strategically advance its ophthalmology and retina franchise. This council, co-led by prominent retina and uveitis specialists, aims to enhance growth strategies for existing products and develop new offerings. The initiative reflects ANI's dedication to serving patients and improving lives in the field of eye care.
Read more →ANIPANI Pharmaceuticals Announces Board Transition
ANI Pharmaceuticals announced a leadership transition as Patrick D. Walsh retires from his role as Chairman of the Board after a significant tenure. Thomas J. Haughey, a board member since 2018, has been elected as the new Chairman. The company is optimistic about its future growth, particularly in its Rare Disease business.
Read more →ANIPANI Pharmaceuticals to Present at the Jefferies Global Healthcare Conference – London
ANI Pharmaceuticals announced that CEO Nikhil Lalwani will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on November 18. The event will be accessible live and archived on the company's website for 90 days. ANI Pharmaceuticals focuses on developing innovative therapeutics across various medical fields.
Read more →ANIPANI Pharmaceuticals Reports Record Third Quarter 2025 Financial Results and Raises 2025 Guidance
ANI Pharmaceuticals reported record financial results for Q3 2025, with total net revenues reaching $227.8 million, a 53.6% increase year-over-year. The Rare Disease segment, particularly Cortrophin Gel, saw exceptional growth, contributing significantly to overall revenues. The company has raised its 2025 financial guidance, anticipating a year-over-year revenue growth of 39% to 42%. ANI remains focused on expanding its Rare Disease business to enhance shareholder value.
Read more →ANIPANI Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 7, 2025, at 8:30 a.m. ET
ANI Pharmaceuticals will announce its third quarter 2025 financial results on November 7, 2025. The announcement will be followed by a conference call featuring key executives to discuss the results. A replay of the call will be available for two weeks. The company emphasizes its commitment to developing innovative therapeutics.
Read more →ANIPANI Pharmaceuticals Announces NEW DAY Clinical Trial Results to be Presented in Late-Breaking Oral Presentation at the American Academy of Ophthalmology 2025 Meeting
ANI Pharmaceuticals announced that results from the NEW DAY clinical trial of ILUVIEN for diabetic macular edema will be presented at the AAO 2025 Meeting. The late-breaking oral presentation will take place on October 17, 2025, by Dr. Victor H. Gonzalez. This event represents a significant opportunity for ANI to engage with the ophthalmology community regarding their findings.
Read more →ANIPANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN® for Use in Patients with Diabetic Macular Edema (DME)
ANI Pharmaceuticals announced results from the NEW DAY clinical trial evaluating ILUVIEN for diabetic macular edema (DME). While the primary endpoint of reducing supplemental aflibercept injections was not statistically significant, secondary endpoints showed promising results, including a significant increase in time to the first supplemental injection. The trial demonstrated ILUVIEN's potential to alleviate treatment burden for patients with DME.
Read more →ANIPANI Pharmaceuticals to Participate at Leerink Partners Therapeutics Forum: I&I and Metabolism on July 8th
ANI Pharmaceuticals is set to participate in the Leerink Partners Therapeutics Forum on July 8, 2025. CEO Nikhil Lalwani will host one-on-one meetings at the event in Boston, MA. This participation underscores ANI's commitment to engaging with investors and showcasing its diverse biopharmaceutical portfolio.
Read more →ANIPANI Pharmaceuticals Announces Presentation of New Preclinical Data
ANI Pharmaceuticals announced promising preclinical data for Cortrophin Gel, demonstrating its effectiveness in reducing joint swelling and inflammatory responses in a mouse model of collagen-induced arthritis. The study, presented at the EULAR 2025 Congress, highlights the drug's potential without causing adverse effects on bone turnover. This research underscores ANI's commitment to advancing treatment options for patients.
Read more →Competitive Position
How ANIP ranks across every disease it competes inCompetitive Position is a premium feature
See how ANIP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial